Article PDF
Avoid common mistakes on your manuscript.
References
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022). Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663.
Chen, J., Wang, R., Gilby, N.B., and Wei, G.W. (2022). Omicron Variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model 62, 412–422.
Gstöttner, C., Zhang, T., Resemann, A., Ruben, S., Pengelley, S., Suckau, D., Welsink, T., Wuhrer, M., and Domínguez-Vega, E. (2021). Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells. Anal Chem 93, 6839–6847.
Jiang, S., Zhang, X., and Du, L. (2021). Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. Expert Opin Ther Targets 25, 415–421.
Lazarevic, I., Pravica, V., Miljanovic, D., and Cupic, M. (2021). Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far? Viruses 13, 1192.
Li, B., Deng, A., Li, K., Hu, Y., Li, Z., Shi, Y., Xiong, Q., Liu, Z., Guo, Q., Zou, L., et al. (2022). Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. Nat Commun 13, 460–468.
Li, T., Tang, X., Wu, C., Yao, X., Wang, Y., Lu, X., and Lu, J. (2020). The use of SARS-CoV-2-related coronaviruses from bats and pangolins to polarize mutations in SARS-Cov-2. Sci China Life Sci 63, 1608–1611.
Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T.S., Ngare, I., Kimura, I., Uriu, K., Kosugi, Y., et al. (2021). SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microb 29, 1124–1136.e11.
Mu, J., Xu, J., Zhang, L., Shu, T., Wu, D., Huang, M., Ren, Y., Li, X., Geng, Q., Xu, Y., et al. (2020). SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells. Sci China Life Sci 63, 1413–1416.
Nathan, A., Rossin, E.J., Kaseke, C., Park, R.J., Khatri, A., Koundakjian, D., Urbach, J.M., Singh, N.K., Bashirova, A., Tano-Menka, R., et al. (2021). Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell 184, 4401–4413.e10.
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M.M., Bishop, E., et al. (2021). Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med 27, 917–924.
Rice, A., Verma, M., Shin, A., Zakin, L., Sieling, P., Tanaka, S., Balint, J., Dinkins, K., Adisetiyo, H., Morimoto, B., et al. (2021). Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice. Sci Rep 11, 14917–14932.
Scudellari, M. (2021). How the coronavirus infects cells— and why Delta is so dangerous. Nature 595, 640–644.
VanBlargan, L.A., Errico, J.M., Halfmann, P.J., Zost, S.J., CroweJr., J.E., Purcell, L.A., Kawaoka, Y., Corti, D., Fremont, D.H., and Diamond, M. S. (2022). An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 28, 490–495.
Wen, W., Chen, C., Tang, J., Wang, C., Zhou, M., Cheng, Y., Zhou, X., Wu, Q., Zhang, X., Feng, Z., et al. (2022). Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med 54, 516–523.
Xia, S., Wen, Z., Wang, L., Lan, Q., Jiao, F., Tai, L., Wang, Q., Sun, F., Jiang, S., Lu, L., et al. (2021). Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha). Cell Discov 7, 109–114.
Zhu, X., Mannar, D., Srivastava, S.S., Berezuk, A.M., Demers, J.P., Saville, J.W., Leopold, K., Li, W., Dimitrov, D.S., Tuttle, K.S., et al. (2021). Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. PLoS Biol 19, e3001237–3001254.
Acknowledgements
This work was supported by the National Science Foundation for Excellent Young Scholars (32122052) and the National Natural Science Foundation Regional Innovation and Development (U19A2003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Compliance and ethics The author(s) declare that they have no conflict of interest.
Supplementary Materials
Rights and permissions
About this article
Cite this article
Que, H., Chen, L. & Wei, X. SARS-CoV-2 variants, immune escape, COVID-19 vaccine, and therapeutic strategies. Sci. China Life Sci. 66, 406–410 (2023). https://doi.org/10.1007/s11427-021-2164-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-021-2164-6